Stockwatch: The perils of a successful biotech
This article was originally published in Scrip
Executive Summary
Investors are firmly in the tail of the full-year 2010 earnings season with most of the major pharmaceutical and biotechnology companies having already reported. This leaves a few profitable but mostly loss-making companies still to report the quarter.